CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia

Table 2 Biomarkers of neuroinflammation and neurodegeneration in the diagnostic groups

Diagnosis	Prion disease	AD	FTD	Controls	P
N	101	40	72	40
CHIT1 all (pg/ml), median (IQR)	3669 (1568–8017)	2259 (1603–4944)	2657 (1437–5800)	1409 (783–2537)	< 0.001^a
WT (pg/ml), median (IQR)	4382 (1874–8311)	2399 (1884–4247)	3706 (1776–7374)	2095 (1226–2948)	0.016^a
Het (pg/ml), median (IQR)	4078 (1570–9379)	2065 (1465–5409)	1006 (648–1894)	803 (628–1090)	< 0.001^a
YKL-40 (ng/ml), median (IQR)	315 (222–453)	240 (176–293)	192 (135–257)	145 (115–161)	< 0.001^a
GFAP (ng/ml), median (IQR)	1.028 (0.636–1.698)	1.081 (0.534–1.422)	1.065 (0.667–1.422)	0.665 (0.409–0.978)	0.002^a
t-tau (pg/ml), median (IQR)	4644 (1977–9223)	698 (491–1013)	253 (179–347)	168 (138–228)	< 0.001^a
NfL (pg/ml), median (IQR)	7225 (3879–12,188)	1405 (942–1730)	2805 (1382–5158)	595 (430–831)	< 0.001^a

AD Alzheimer’s disease, CHIT1 chitotriosidase 1, CJD Creutzfeldt-Jakob disease, FTD frontotemporal dementia, GFAP glial fibrillary acidic protein, Het heterozygotes for CHIT1 24-bp duplication, IQR interquartile range, N number, NfL neurofilament light chain protein, t-tau total tau protein, YKL-40 chitinase-3-like protein 1, WT wild type for CHIT1 24-bp duplication
^aKruskal-Wallis test

ISSN: 1758-9193